ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Questionnaire
    • Downloads (US)
    • Downloads (EU)
    • Education

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Account
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar acarix
Press
August 6, 2024
03 Jul 2024

ACARIX GENOMFÖR EN RIKTAD EMISSION OM 21 MSEK

DETTA PRESSMEDDELANDE FÅR INTE OFFENTLIGGÖRAS, DISTRIBUERAS ELLER PUBLICERAS, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRA...
Continue reading
author-avatar acarix
Press
August 6, 2024
03 Jul 2024

ACARIX CARRIES OUT A DIRECTED SHARE ISSUE OF SEK 21 MILLION

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BE...
Continue reading
author-avatar acarix
Press
August 6, 2024
01 Feb 2024

Acarix carries out a directed share issue of approximately SEK 33.7 million

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BE...
Continue reading
author-avatar acarix
Press
August 6, 2024
01 Feb 2024

Acarix genomför en riktad emission om cirka 33,7 MSEK

DETTA PRESSMEDDELANDE ÄR EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AU...
Continue reading
author-avatar acarix
Press
August 6, 2024
16 Nov 2023

ACARIX CARRIES OUT A DIRECTED ISSUE TO GUARANTORS FOLLOWING THE COMPLETED RIGHTS ISSUE

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG ...
Continue reading
author-avatar acarix
Press
August 6, 2024
16 Nov 2023

ACARIX GENOMFÖR RIKTAD NYEMISSION TILL GARANTER EFTER DEN GENOMFÖRDA FÖRETRÄDESEMISSIONEN

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONG...
Continue reading
author-avatar acarix
Press
August 6, 2024
06 Nov 2023

Last day of trading in paid subscribed units in Acarix’ unit rights issue is 9 November 2023

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, ...
Continue reading
author-avatar acarix
Press
August 6, 2024
06 Nov 2023

Sista dag för handel i BTU i Acarix företrädesemission av units är 9 november 2023

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAP...
Continue reading
author-avatar acarix
Press
August 6, 2024
20 Oct 2023

Acarix announces final outcome in the rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, ...
Continue reading
author-avatar acarix
Press
August 6, 2024
20 Oct 2023

Acarix offentliggör slutligt utfall i företrädesemissionen

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAP...
Continue reading
author-avatar acarix
Press
August 6, 2024
18 Oct 2023

Acarix offentliggör preliminärt utfall i företrädesemission

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAP...
Continue reading
author-avatar acarix
Press
August 6, 2024
18 Oct 2023

Acarix announces preliminary outcome of the Rights Issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, ...
Continue reading
  • 1
  • 2
  • 3
  • 4
Acarix AB
Jungmansgatan 12
211 19 Malmö
SE
info@acarix.com

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • Press
  • Events
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2025. All rights reserved V5

  • Products
    • Background
    • What is Coronary Artery Disease
    • Diagnosing CAD
    • About the product
    • The Cadscor System
    • How Does it Work
  • Resources
    • Testimonial
    • HCP Stories
    • Patients Stories
    • References
    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)
    • Support
    • Training
    • Faq
    • Reimbursement
    • Physician Locator
    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
    • About Acarix
    • Leadership
    • Join The Team
    • Get in touch
    • Contact Us
    • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.